Novel approaches to testing for sexually transmitted infections, including HIV and hepatitis B and C in Europe
This report focuses on novel approaches to testing for sexually transmitted infections (STIs), human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) that are relevant for the prevention and control of these infections at EU/EEA level.
‘Novel approaches’ captures both technical advances in STI, HIV, HBV and HCV tests as well as new opportunities for initiating and conducting testing and managing results, treatment and surveillance that the changes in technology facilitate.
Effective testing strategies are vital for the control of sexually transmitted infections (STI), human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) as accurate testing allows treatment of those infected and subsequent reduction in infectiousness. In addition, it leads to a reduction of clinical consequences, identification and treatment of potentially infected partners as well as opportunities for health promotion and behaviour modification due to awareness of infection.Recent changes in the field of testing for STI, HIV, HBV and HCV include the widespread implementation of nucleic acid amplification technologies (NAATs) for chlamydia and gonorrhoea diagnosis or the development of HIV screening tests that are easy to use and give a result almost immediately. Novel approaches in testing cover both technical advances in STI, HIV and hepatitis B and C tests as well as new opportunities for initiating and conducting testing and managing results, treatment and surveillance that changes in technology facilitate. The report Novel approaches to testing for sexually transmitted infections, including HIV and hepatitis B and C in Europe concludes that new testing technologies combined with modern information and communication systems will enable the development of novel testing pathways. These novel approaches have the potential to improve access to (and hence the uptake of) testing among individuals and population groups at risk of infections as well as increase the proportion of infected individuals treated earlier in infection. These novel approaches will have a clinical impact by improving the prognosis for those with infections as well as the public health impact by reducing onward transmission and thus incidence and prevalence of infection.
Interim public health considerations for COVID-19 vaccination of children aged 5-11 years
1 Dec 2021 - This technical report provides a set of interim public health considerations to support EU/EEA public health authorities taking decisions on the administration of COVID-19 vaccines to children aged 5 11 years.
Surveillance of COVID-19 in long-term care facilities in the EU/EEA
29 Nov 2021 - ECDC has worked with EU/EEA countries to develop a methodology for regular national reporting of existing national surveillance data on COVID-19 in LTCFs, aiming for maximum feasibility. This is to enable ECDC to communicate timely information on epidemiological trends of COVID-19 in LTCFs, in support of national and EU/EEA-level preparedness and response activities.
Assessment of electronic health records for infectious disease surveillance
19 Nov 2021 - This is the final report for the mapping study ‘Assessment of electronic health records (EHRs) for infectious disease surveillance, prevention and control’. The study was commissioned by ECDC and was delivered by RAND Europe. The objective of the project is to investigate the current status of EHR systems in the European Union and European Economic Area (EU/EEA) and the potential capacity for the use of these data for surveillance of infectious diseases within ECDC’s remit.